Nixon, Mellissa J.
Formisano, Luigi
Mayer, Ingrid A.
Estrada, M. Valeria
González-Ericsson, Paula I. http://orcid.org/0000-0002-6292-6963
Isakoff, Steven J.
Forero-Torres, Andrés
Won, Helen
Sanders, Melinda E.
Solit, David B. http://orcid.org/0000-0002-6614-802X
Berger, Michael F.
Cantley, Lewis C.
Winer, Eric P.
Arteaga, Carlos L.
Balko, Justin M. http://orcid.org/0000-0002-4263-5974
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P50 CA098131, P30 CA68485, K23 CA127469-01A2, R01 GM041890)
Article History
Received: 28 November 2018
Accepted: 28 August 2019
First Online: 23 September 2019
Competing interests
: J.M.B. receives consulting fees from Novartis (not pertaining to alpelisib or buparlisib), and research support from Genentech and Incyte Pharma. M.B. receives consulting fees from Roche and research support from Illumina. I.A.M. receives research funding from Novartis, Pfizer, and Genentech and adboards/consulting fees from Novartis, Genentech, Lilly, Astra-Zeneca, GSK, Immunomedics, Macrogenics and Seattle Genetics. C.L.A. receives research funding from Pfizer, Lilly, Radius, and PUMA Biotechnology, stock options from Provista, and holds advisory roles with Daichii Sankyo, TAIHO Oncology, Novartis, Merck, and Lilly. D.S. has received consulting fees from Pfizer, Loxo Oncology, Lilly Oncology, Vivideon Therapeutics and Illumina. L.C.C. owns equity in, receives compensation from, and serves on the scientific advisory board of Agios Pharmaceuticals. He is also a founder of and receives laboratory support from Petra Pharmaceuticals and receives compensation for being on the scientific advisory board of Petra Pharmaceuticals. No drugs from these companies were involved in this study. S.J.I. receives research funding support (to his institution) from Genentech, PharmaMar, AstraZeneca, and Merck and receives consulting fees from Genentech, Hengrui, Puma, Immunomedics, and Myriad Genetics. The remaining authors declare no competing interests.